Novavax Net Cash Flow from Investing vs Issuance Purchase of Equity Shares Analysis

NVAX Stock

USD 3.89 0.10 2.51%

Trend analysis of Novavax balance sheet accounts such as Property Plant And Equipment Net of 515.5 M provides information on Novavax's total assets, liabilities, and equity, which is the actual value of Novavax to its prevalent stockholders. By breaking down trends over time using Novavax balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

About Novavax Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Novavax at a specified time, usually calculated after every quarter, six months, or one year. Novavax Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Novavax and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Novavax currently owns. An asset can also be divided into two categories, current and non-current.

Novavax Balance Sheet Chart

Novavax Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Novavax uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Novavax's Liabilities And Stockholders Equity is fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 4.3 B in 2024, despite the fact that Total Stockholder Equity is likely to grow to (681.1 M).

Total Assets Total Current Liabilities Property Plant And Equipment Net Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Novavax assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Novavax books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Novavax balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Novavax are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Accounts Payable

An accounting item on the balance sheet that represents Novavax obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Novavax are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2024, despite the fact that Tax Provision is likely to grow to (1.8 M).

Novavax fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.78	0.94	-0.56	0.87	-0.87	-0.91	0.93	0.94	0.9	0.94	0.94	0.93	0.8	0.94	0.96	0.86	0.99	0.88	0.78	-0.46	0.71	-0.41	0.67	-0.37	0.33
Other Current Liab	0.78		0.9	-0.89	0.91	-0.66	-0.9	0.93	0.72	0.88	0.75	0.68	0.84	0.55	0.85	0.9	0.91	0.7	0.55	0.66	-0.35	0.53	-0.32	0.34	-0.26	0.02
Total Current Liabilities	0.94	0.9		-0.75	0.86	-0.88	-0.92	0.96	0.94	0.87	0.93	0.92	0.88	0.83	0.89	0.98	0.86	0.92	0.76	0.67	-0.4	0.68	-0.41	0.55	-0.36	0.21
Total Stockholder Equity	-0.56	-0.89	-0.75		-0.74	0.4	0.79	-0.72	-0.53	-0.71	-0.63	-0.45	-0.69	-0.4	-0.69	-0.76	-0.75	-0.48	-0.4	-0.62	0.35	-0.56	0.21	-0.06	0.15	-0.19
Property Plant And Equipment Net	0.87	0.91	0.86	-0.74		-0.62	-0.96	0.91	0.7	0.99	0.77	0.69	0.97	0.46	0.96	0.92	1.0	0.78	0.74	0.87	-0.43	0.56	-0.36	0.46	-0.3	0.14
Net Debt	-0.87	-0.66	-0.88	0.4	-0.62		0.67	-0.82	-0.94	-0.65	-0.87	-0.94	-0.67	-0.9	-0.68	-0.8	-0.61	-0.91	-0.74	-0.38	0.22	-0.45	0.47	-0.6	0.46	-0.03
Retained Earnings	-0.91	-0.9	-0.92	0.79	-0.96	0.67		-0.93	-0.8	-0.97	-0.86	-0.77	-0.98	-0.6	-0.99	-0.97	-0.96	-0.85	-0.77	-0.89	0.5	-0.72	0.34	-0.48	0.28	-0.33
Accounts Payable	0.93	0.93	0.96	-0.72	0.91	-0.82	-0.93		0.89	0.91	0.83	0.88	0.9	0.74	0.92	0.96	0.91	0.89	0.68	0.7	-0.41	0.67	-0.4	0.65	-0.36	0.17
Cash	0.94	0.72	0.94	-0.53	0.7	-0.94	-0.8	0.89		0.73	0.92	0.99	0.77	0.95	0.8	0.9	0.69	0.97	0.76	0.57	-0.4	0.73	-0.41	0.71	-0.39	0.34
Non Current Assets Total	0.9	0.88	0.87	-0.71	0.99	-0.65	-0.97	0.91	0.73		0.81	0.72	0.99	0.49	0.98	0.93	0.99	0.82	0.79	0.89	-0.44	0.59	-0.35	0.47	-0.29	0.19
Non Currrent Assets Other	0.94	0.75	0.93	-0.63	0.77	-0.87	-0.86	0.83	0.92	0.81		0.9	0.85	0.82	0.86	0.94	0.77	0.94	0.9	0.71	-0.43	0.66	-0.44	0.45	-0.41	0.35
Cash And Short Term Investments	0.94	0.68	0.92	-0.45	0.69	-0.94	-0.77	0.88	0.99	0.72	0.9		0.76	0.94	0.79	0.88	0.67	0.98	0.77	0.55	-0.41	0.7	-0.4	0.74	-0.38	0.32
Common Stock Shares Outstanding	0.93	0.84	0.88	-0.69	0.97	-0.67	-0.98	0.9	0.77	0.99	0.85	0.76		0.55	0.99	0.95	0.97	0.86	0.84	0.92	-0.48	0.65	-0.39	0.5	-0.34	0.29
Other Current Assets	0.8	0.55	0.83	-0.4	0.46	-0.9	-0.6	0.74	0.95	0.49	0.82	0.94	0.55		0.59	0.75	0.45	0.87	0.61	0.33	-0.32	0.68	-0.36	0.67	-0.36	0.34
Other Stockholder Equity	0.94	0.85	0.89	-0.69	0.96	-0.68	-0.99	0.92	0.8	0.98	0.86	0.79	0.99	0.59		0.96	0.96	0.87	0.82	0.91	-0.5	0.7	-0.34	0.54	-0.28	0.33
Total Liab	0.96	0.9	0.98	-0.76	0.92	-0.8	-0.97	0.96	0.9	0.93	0.94	0.88	0.95	0.75	0.96		0.92	0.92	0.82	0.81	-0.47	0.73	-0.39	0.54	-0.34	0.32
Property Plant And Equipment Gross	0.86	0.91	0.86	-0.75	1.0	-0.61	-0.96	0.91	0.69	0.99	0.77	0.67	0.97	0.45	0.96	0.92		0.77	0.73	0.87	-0.42	0.55	-0.36	0.43	-0.29	0.13
Total Current Assets	0.99	0.7	0.92	-0.48	0.78	-0.91	-0.85	0.89	0.97	0.82	0.94	0.98	0.86	0.87	0.87	0.92	0.77		0.87	0.7	-0.45	0.71	-0.41	0.72	-0.38	0.36
Net Receivables	0.88	0.55	0.76	-0.4	0.74	-0.74	-0.77	0.68	0.76	0.79	0.9	0.77	0.84	0.61	0.82	0.82	0.73	0.87		0.77	-0.38	0.49	-0.46	0.41	-0.43	0.31
Non Current Liabilities Total	0.78	0.66	0.67	-0.62	0.87	-0.38	-0.89	0.7	0.57	0.89	0.71	0.55	0.92	0.33	0.91	0.81	0.87	0.7	0.77		-0.55	0.7	-0.24	0.39	-0.18	0.52
Intangible Assets	-0.46	-0.35	-0.4	0.35	-0.43	0.22	0.5	-0.41	-0.4	-0.44	-0.43	-0.41	-0.48	-0.32	-0.5	-0.47	-0.42	-0.45	-0.38	-0.55		-0.59	0.11	-0.32	0.08	-0.53
Short Long Term Debt Total	0.71	0.53	0.68	-0.56	0.56	-0.45	-0.72	0.67	0.73	0.59	0.66	0.7	0.65	0.68	0.7	0.73	0.55	0.71	0.49	0.7	-0.59		-0.12	0.65	-0.1	0.82
Common Stock Total Equity	-0.41	-0.32	-0.41	0.21	-0.36	0.47	0.34	-0.4	-0.41	-0.35	-0.44	-0.4	-0.39	-0.36	-0.34	-0.39	-0.36	-0.41	-0.46	-0.24	0.11	-0.12		-0.34	0.99	0.09
Short Term Debt	0.67	0.34	0.55	-0.06	0.46	-0.6	-0.48	0.65	0.71	0.47	0.45	0.74	0.5	0.67	0.54	0.54	0.43	0.72	0.41	0.39	-0.32	0.65	-0.34		-0.34	0.37
Common Stock	-0.37	-0.26	-0.36	0.15	-0.3	0.46	0.28	-0.36	-0.39	-0.29	-0.41	-0.38	-0.34	-0.36	-0.28	-0.34	-0.29	-0.38	-0.43	-0.18	0.08	-0.1	0.99	-0.34		0.09
Long Term Debt	0.33	0.02	0.21	-0.19	0.14	-0.03	-0.33	0.17	0.34	0.19	0.35	0.32	0.29	0.34	0.33	0.32	0.13	0.36	0.31	0.52	-0.53	0.82	0.09	0.37	0.09

Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Liab	19.9M	(327.6M)	709.8M	1.5B	1.2B	1.3B
Total Current Liabilities	25.8M	322.0M	2.4B	2.5B	1.6B	1.7B
Total Stockholder Equity	(186.0M)	627.2M	(351.7M)	(634.1M)	(716.9M)	(681.1M)
Property Plant And Equipment Net	11.4M	180.0M	228.7M	400.5M	491.0M	515.5M
Net Debt	243.1M	(231.4M)	(1.1B)	(787.1M)	(298.3M)	(283.4M)
Retained Earnings	(1.4B)	(1.9B)	(3.6B)	(4.3B)	(4.8B)	(4.6B)
Accounts Payable	2.9M	54.3M	127.1M	216.5M	132.6M	139.2M
Cash	78.8M	553.4M	1.5B	1.3B	578.9M	607.9M
Non Current Assets Total	75.7M	334.3M	421.6M	555.3M	711.5M	747.0M
Non Currrent Assets Other	7.5M	13.2M	56.7M	28.5M	30.3M	31.8M
Cash And Short Term Investments	78.8M	711.0M	1.5B	1.3B	578.9M	607.9M
Common Stock Shares Outstanding	24.1M	57.6M	74.4M	78.2M	100.8M	105.8M
Liabilities And Stockholders Equity	173.0M	1.6B	2.6B	2.3B	1.9B	1.9B
Other Current Assets	93.9M	441.8M	2.1B	1.7B	226.0M	191.7M
Other Stockholder Equity	1.3B	2.5B	3.3B	3.6B	4.1B	4.3B
Total Liab	359.0M	955.3M	2.9B	2.9B	2.6B	2.7B
Property Plant And Equipment Gross	11.4M	180.0M	258.6M	447.8M	566.0M	594.3M
Total Current Assets	97.2M	1.2B	2.2B	1.7B	1.1B	1.2B
Accumulated Other Comprehensive Income	(12.5M)	7.0M	(1.4M)	(6.4M)	2.7M	2.9M
Net Receivables	7.5M	262.0M	455.0M	82.4M	297.2M	312.1M
Non Current Liabilities Total	333.2M	633.2M	538.1M	432.8M	937.1M	984.0M
Intangible Assets	6.5M	5.6M	5.7M	4.8M	4.3M	4.1M
Short Long Term Debt Total	321.9M	322.0M	454.0M	549.8M	280.6M	294.7M
Common Stock Total Equity	3.8M	324K	714K	764K	878.6K	1.3M
Short Term Debt	1.3M	322.0M	130.5M	352.1M	28.1M	43.9M
Common Stock	324K	714K	764K	868K	1.4M	1.3M
Long Term Debt	320.6M	322.0M	323.5M	166.5M	168.0M	114.6M
Inventory	(83.0M)	(166.7M)	(2.0B)	36.7M	41.7M	43.8M
Property Plant Equipment	11.4M	180.0M	228.7M	400.5M	460.6M	483.6M
Other Liab	2.6M	3.4M	175.5M	185.0M	212.8M	223.4M
Current Deferred Revenue	1.7M	273.2M	1.4B	370.1M	241.3M	140.2M
Other Assets	1.1M	5.4M	16.6M	28.5M	32.7M	34.4M
Good Will	51.2M	135.4M	131.5M	126.3M	127.5M	133.8M
Net Tangible Assets	(242.8M)	486.1M	(487.9M)	(760.4M)	(684.4M)	(650.1M)
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.9B)	(3.6B)	(3.3B)	(3.1B)
Long Term Debt Total	319.2M	320.6M	322.0M	323.5M	372.0M	234.9M
Capital Surpluse	1.1B	1.3B	2.5B	3.4B	3.9B	4.0B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novavax offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novavax's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novavax Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novavax Stock:

How To Invest In Novavax

Details

Is Novavax Stock a good investment?

Details

What is Novavax's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Note that the Novavax information on this page should be used as a complementary analysis to other Novavax's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Complementary Tools for Novavax Stock analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Stocks Directory Find actively traded stocks across global markets
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios

Is Novavax's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novavax. If investors know Novavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novavax listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.41)

Revenue Per Share

9.762

Quarterly Revenue Growth

(0.18)

Return On Assets

(0.17)

Return On Equity

(8.98)

The market value of Novavax is measured differently than its book value, which is the value of Novavax that is recorded on the company's balance sheet. Investors also form their own opinion of Novavax's value that differs from its market value or its book value, called intrinsic value, which is Novavax's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novavax's market value can be influenced by many factors that don't directly affect Novavax's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novavax's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novavax is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novavax's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novavax Net Cash Flow from Investing vs Issuance Purchase of Equity Shares Analysis

About Novavax Balance Sheet Analysis

Novavax Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Accounts Payable

Novavax fundamental ratios Correlations

Novavax Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novavax fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novavax Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Cash And Short Term Investments	+ 0.99	Cash
Common Stock Shares Outstanding	+ 0.99	Non Current Assets Total
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Non Current Assets Total	- 0.97	Retained Earnings
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net